ORTX - Orchard Therapeutics plc Stock Price, Fair Value and News

16.70USD Market Closed

Market Summary

USD16.70

Market Closed

ORTX Stock Price

View Fullscreen

ORTX RSI Chart

ORTX Valuation

Market Cap

3.8B

Price/Earnings (Trailing)

-52.13

Price/Sales (Trailing)

174.05

EV/EBITDA

-56.73

Price/Free Cashflow

-40.26

ORTX Price/Sales (Trailing)

ORTX Profitability

EBT Margin

-334.54%

Return on Equity

-90.86%

Return on Assets

-36.05%

Free Cashflow Yield

-2.48%

ORTX Fundamentals

ORTX Revenue

Revenue (TTM)

21.8M

ORTX Earnings

Earnings (TTM)

-72.9M

Breaking Down ORTX Revenue

Last 30 days

1.5%

Last 90 days

5.0%

Trailing 12 Months

200.0%

How does ORTX drawdown profile look like?

ORTX Financial Health

Current Ratio

3.12

Debt/Equity

0.31

Debt/Cashflow

-3.76

ORTX Investor Care

Shares Dilution (1Y)

1696.60%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	18.4M	21.3M	21.8M	0
2022	7.2M	11.6M	16.2M	22.7M
2021	0	0	3.8M	3.7M
2020	0	3.8M	5.1M	3.2M
2019	0	0	3.3M	4.6M
2018	0	0	0	2.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Orchard Therapeutics plc

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

CEO	Dr. Bobby Gaspar M.D., Ph.D.
WEBSITE	orchard-tx.com
INDUSTRY	Biotechnology
EMPLOYEES	166

Orchard Therapeutics plc Frequently Asked Questions

What is the ticker symbol for Orchard Therapeutics plc? What does ORTX stand for in stocks?

ORTX is the stock ticker symbol of Orchard Therapeutics plc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Orchard Therapeutics plc (ORTX)?

As of Fri Feb 02 2024, market cap of Orchard Therapeutics plc is 3.8 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORTX stock?

You can check ORTX's fair value in chart for subscribers.

Is Orchard Therapeutics plc a good stock to buy?

The fair value guage provides a quick view whether ORTX is over valued or under valued. Whether Orchard Therapeutics plc is cheap or expensive depends on the assumptions which impact Orchard Therapeutics plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORTX.

What is Orchard Therapeutics plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 02 2024, ORTX's PE ratio (Price to Earnings) is -52.13 and Price to Sales (PS) ratio is 174.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORTX PE ratio will change depending on the future growth rate expectations of investors.